SeqOne, a Montpellier, France-based AI-driven genomic analysis company focused on personalized medicine, has raised €20 million growth funding round.
Investors
The oversubscribed round was led by Supernova Invest, with continued support from Elaia, Omnes, and Mérieux Equity Partners.
Mérieux Equity Partners (MxEP) is an AMF-accredited investment firm specializing in the healthcare sector. With over €1.5 billion in assets under management across two dedicated strategies—Innovation and Buyout—MxEP supports companies ranging from start-ups to established industry leaders.
SeqOne Use of Funds
The company will use the funding to scale international operations, accelerate growth in the U.S. market, and pursue strategic acquisitions to expand capabilities.
About SeqOne
SeqOne is a deep-tech company committed to making personalized medicine a reality. Its AI-powered genomic analysis platform provides clinical decision-support tools that enable molecular laboratories to deliver fast, accurate, and scalable analyses of genetic data for applications in oncology, rare diseases, and—through recent acquisitions—multi-omics, including pathogen detection. With 140 active lab customers across 22 countries and a projection to process over 110,000 patient analyses in 2025, SeqOne serves a growing global customer base of healthcare providers and biopharmaceutical companies.
Funding Details
Company: SeqOne SAS
Raised: €20.0M
Round: Growth Funding
Funding Date: May 2025
Lead Investor: Supernova Invest
Additional Investors: Elaia, Omnes, Mérieux Equity Partners
Company Website: https://www.seqone.com/
Software Category: Genomic Analysis / AI-Driven Personalized Medicine
Source: https://www.seqone.com/news-insights/seqone-genomics-raises-eu20-million-in-oversubscribed-growth-round-to-lead-ai-powered-ngs-revolution-in-personalized-medicine